摘要
目的:探讨赫赛汀治疗HER-2过度表达的乳腺癌患者临床疗效和护理。方法:选取2016.02—2017.11来我院就诊的96例HER-2过度表达的乳腺癌患者为研究对照,根据治疗方式的不同,分为观察组和对照组,每组48例。对照组给予多柔比星+环磷酰胺(4个疗程),再加紫杉醇(4个疗程)的常规化疗方式,观察组在常规化疗的基础上于第5个疗程,联合赫赛汀以联合化疗方式进行治疗,根据患者的状态,均给予积极护理,比较两组患者的临床疗效。结果:观察组的临床缓解率为81.25%,显著高于对照组的35.42%,差异有统计学意义,P<0.05;所有患者均顺利完成化疗过程,未出现严重的毒副反应,患者依从性良好。结论:赫赛汀联合化疗对HER-2过度表达的乳腺癌患者临床疗效显著,而积极有效的护理可显著降低治疗过程中的不良反应,提高患者的依从性,值得临床推广应用。
Objective： To investigate the clinical efficacy and nursing of Herceptin in the treatment of HER-2 overexpressing breast cancer. Methods： A total of 96 HER-2 overexpressing breast cancer patients from 2016.02 to 2017.11 in our hospital were selected as the research control. According to the different treatment methods, the patients were divided into observation group and control group, with 48 cases in each group. The control group was given doxorubicin＋cyclophosphamide（4 courses）, plus paclitaxel（4 courses） of conventional chemotherapy; on the basis of conventional chemotherapy, the observation group was treated with the combination chemotherapy of the 5 th course and Herceptin. According to the state of the patients, the observation group was given active nursing care. The clinical efficacy of the two groups was compared. Results： The clinical remission rate in observation group was 81.25%, which was significantly higher than that in control group（35.42%）（P〈0.05）. All patients successfully completed the chemotherapy without serious adverse reactions and patient compliance good. Conclusion： Herceptin combined with chemotherapy has significant clinical effect on breast cancer patients with overexpression of HER-2. Active and effective nursing can significantly reduce adverse reactions during treatment and improve patient compliance, which is worthy of clinical application.
出处
《药品评价》
CAS
2018年第2期50-53,共4页
Drug Evaluation
